tiprankstipranks
Trending News
More News >
Solventum Corporation (SOLV)
:SOLV
US Market
Advertisement

Solventum Corporation (SOLV) AI Stock Analysis

Compare
246 Followers

Top Page

SOLV

Solventum Corporation

(NYSE:SOLV)

Rating:66Neutral
Price Target:
$80.00
▲(7.02%Upside)
Solventum exhibits strong growth, particularly in the MedSurg and HIS segments, along with a positive earnings call that enhances its outlook. However, financial stability concerns due to high leverage and declining cash flow, coupled with a premium valuation, temper the overall score. The technical indicators suggest potential short-term weakness.
Positive Factors
Debt Management
Net proceeds from the transaction are primarily intended to pay down debt.
Earnings
Analyst's recommendation to upgrade SOLV shares to Overweight reflects improved visibility on top-line performance and reduced tariff risks.
Valuation
SOLV's shares are considered undervalued compared to similar companies, trading at a relatively low multiple, which suggests potential for price appreciation.
Negative Factors
Gross Margin
The transaction is a headwind on Solventum's 200bps gross margin and 100bps operating margin targets due to lower margins in the purification and filtration business.
Margin Pressure
Tariff impacts are pressuring margins with adjusted operating margins expected at the low end of their range.
Market Performance
SOLV shares have underperformed since the spin and trade below large-cap MedTech peers.

Solventum Corporation (SOLV) vs. SPDR S&P 500 ETF (SPY)

Solventum Corporation Business Overview & Revenue Model

Company DescriptionSolventum Corporation (SOLV) is a leading company in the renewable energy sector, specializing in the development, production, and distribution of sustainable energy solutions. The company focuses on harnessing solar, wind, and hydropower technologies to provide clean and efficient energy to both commercial and residential clients. With a commitment to innovation and sustainability, Solventum aims to reduce carbon footprints and promote environmentally friendly energy alternatives.
How the Company Makes MoneySolventum Corporation generates revenue through a diversified model that includes the sale of electricity generated from its renewable energy assets, such as solar farms, wind turbines, and hydroelectric plants. Additionally, the company offers energy management services and consulting to optimize energy usage for its clients. Solventum also engages in strategic partnerships with government bodies and private enterprises to expand its reach and scale its operations, further contributing to its revenue streams. These partnerships often involve long-term power purchase agreements (PPAs) that provide stable and predictable income over time.

Solventum Corporation Earnings Call Summary

Earnings Call Date:May 08, 2025
(Q1-2025)
|
% Change Since: 12.19%|
Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment Neutral
Solventum reported strong growth across its business segments and raised its sales growth guidance, indicating positive momentum. However, the company faces significant challenges from tariffs that will impact profitability in the second half of the year.
Q1-2025 Updates
Positive Updates
Strong Start to 2025
Solventum began fiscal year 2025 with a strong performance, showcasing 4.3% organic sales growth and adjusted earnings per share of $1.34, marking four consecutive quarters of positive growth.
MedSurg Segment Performance
The MedSurg business reported a very strong quarter, achieving 6% organic growth driven by positive business performance and favorable order timing.
Dental Solutions and New Product Launches
The Dental Solutions segment showed resilience with new product launches like Filtek Easy Match and Clarity Precision Grip Attachments, aiding in offsetting market challenges.
Health Information Systems Growth
The HIS segment saw a 3.9% increase in revenue, driven by strong customer retention in Revenue Cycle Management software solutions.
Purification & Filtration Segment Demand
The Purification & Filtration segment experienced robust demand for bioprocessing solutions, indicating strength in end markets.
Guidance Adjustment
Solventum raised its full-year organic sales growth guidance to 1.5% to 2.5%, reflecting strong business momentum.
Negative Updates
Tariff Challenges
Tariffs are expected to be a significant headwind, with an estimated impact of $80 million to $100 million in 2025, affecting gross margins and operating margins in the second half of the year.
Gross Margin Decline
Gross margins decreased by 260 basis points compared to the prior year, due to increased costs and seasonality.
Company Guidance
In the first quarter of fiscal year 2025, Solventum demonstrated robust financial performance, prompting an increase in their organic revenue guidance to 1.5% to 2.5% for the year. The company reported a 4.3% organic sales growth and adjusted earnings per share (EPS) of $1.34, marking their fourth consecutive quarter of positive growth. Despite facing headwinds from tariffs, Solventum maintained its EPS guidance between $5.45 and $5.65 by leveraging favorable foreign exchange rates and implementing mitigation strategies. The MedSurg segment led with a 6% organic growth, driven by improved commercial execution and successful product launches. The Dental Solutions segment showed resilience with a 0.4% growth amidst market challenges. Solventum's focus remains on executing its transformation plan, enhancing commercial productivity, and investing in growth areas to deliver sustainable improvement and shareholder value.

Solventum Corporation Financial Statement Overview

Summary
Solventum Corporation maintains solid profitability with stable revenue growth. However, increasing leverage and declining cash flow generation may pose risks to financial stability. The company should focus on improving operational efficiency and managing debt levels to enhance future financial performance.
Income Statement
70
Positive
Solventum Corporation shows strong gross and net profit margins, indicating effective cost management. However, there's a noticeable decline in both EBIT and EBITDA margins from prior periods, suggesting potential pressure on operational efficiency. Revenue growth is modest, pointing to stable but unspectacular sales performance.
Balance Sheet
65
Positive
The company exhibits a high debt-to-equity ratio, which could indicate significant leverage and potential financial risk. The return on equity is reasonable, reflecting moderate profitability relative to shareholder investment. The equity ratio remains stable, showcasing a balanced approach to asset financing.
Cash Flow
60
Neutral
Solventum's free cash flow has decreased significantly, signaling potential challenges in generating cash from operations. The operating cash flow to net income ratio is healthy, indicating good cash conversion from profits. However, the decline in free cash flow growth rate suggests potential future liquidity concerns.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue8.25B8.20B8.13B8.17B
Gross Profit4.59B4.69B4.70B4.92B
EBITDA1.53B2.23B2.27B2.48B
Net Income479.00M1.35B1.34B1.46B
Balance Sheet
Total Assets14.46B14.38B13.59B14.07B
Cash, Cash Equivalents and Short-Term Investments762.00M600.00M61.00M91.00M
Total Debt8.01B8.30B95.00M83.00M
Total Liabilities11.50B10.97B1.85B2.02B
Stockholders Equity2.96B3.41B11.74B12.06B
Cash Flow
Free Cash Flow805.00M1.63B1.43B1.93B
Operating Cash Flow1.19B1.92B1.68B2.20B
Investing Cash Flow-380.00M-230.00M-253.00M-278.00M
Financing Cash Flow-240.00M-1.55B-1.46B-1.96B

Solventum Corporation Technical Analysis

Technical Analysis Sentiment
Positive
Last Price74.75
Price Trends
50DMA
74.20
Positive
100DMA
72.46
Positive
200DMA
72.08
Positive
Market Momentum
MACD
-0.13
Positive
RSI
52.49
Neutral
STOCH
54.71
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SOLV, the sentiment is Positive. The current price of 74.75 is below the 20-day moving average (MA) of 74.87, above the 50-day MA of 74.20, and above the 200-day MA of 72.08, indicating a neutral trend. The MACD of -0.13 indicates Positive momentum. The RSI at 52.49 is Neutral, neither overbought nor oversold. The STOCH value of 54.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SOLV.

Solventum Corporation Risk Analysis

Solventum Corporation disclosed 39 risk factors in its most recent earnings report. Solventum Corporation reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Solventum Corporation Peers Comparison

Overall Rating
UnderperformOutperform
Sector (56)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
$15.51B23.294.36%0.10%-0.91%27.17%
73
Outperform
$10.02B8.7418.35%0.51%9.73%51.87%
70
Outperform
$10.96B14.37260.92%5.11%14.28%
67
Neutral
$13.78B9.7941.09%-1.09%-43.10%
66
Neutral
$12.93B34.4410.63%1.28%-70.82%
65
Neutral
$10.80B22.1225.33%0.63%11.21%30.38%
56
Neutral
$6.23B21.98-28.61%4.90%10.73%-32.66%
* General Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SOLV
Solventum Corporation
74.75
17.41
30.36%
DVA
DaVita
145.17
6.01
4.32%
FMS
Fresenius Medical Care
26.43
6.45
32.28%
EHC
Encompass Health
107.67
16.78
18.46%
THC
Tenet Healthcare
153.02
0.15
0.10%
UHS
Universal Health
155.60
-60.96
-28.15%

Solventum Corporation Corporate Events

M&A Transactions
Solventum Amends Acquisition Deal with Thermo Fisher
Neutral
Jun 25, 2025

On June 25, 2025, Solventum Corporation and Thermo Fisher Scientific Inc. amended their transaction agreement to exclude Solventum’s drinking water filtration business from the acquisition, reducing the purchase price to approximately $4.00 billion. This amendment is expected to simplify the transaction and potentially accelerate its completion by the end of 2025, while retaining the Water Business could enhance Solventum’s earnings per share but may impact projected margin improvements.

The most recent analyst rating on (SOLV) stock is a Buy with a $82.00 price target. To see the full list of analyst forecasts on Solventum Corporation stock, see the SOLV Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 24, 2025